Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49:499–505
De Felice LJ, Glennon RA, Negus SS (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci 97:20–26
Schechter MD, Glennon RA (1985) Cathinone, cocaine and methamphetamine: similarity of behavioral effects. Pharmacol Biochem Behav 22:913–916
Iversen L, White M, Treble R (2014) Designer psychostimulants: pharmacology and differences. Neuropharmacology 87:59–65
Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, Sandtner W, Ecker GF, Sitte HH, Baumann MH (2015) ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40:1321–1331
Hoffman BJ, Hansson SR, Mezey E, Palkovits M (1998) Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol 19:187–231
Tao-Cheng JH, Zhou FC (1999) Differential polarization of serotonin transporters in axons versus soma-dendrites: an immunogold electron microscopy study. Neuroscience 94:821–830
Wimalasena K (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev 31:483–519
Schloss P, Williams DC (1998) The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol 12:115–121
Stahl SM (1998) Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59(Suppl 4):5–14
Coppen A, Shaw DM, Herzberg B, Maggs R (1967) Tryptophan in the treatment of depression. Lancet 2:1178–1180
Feighner JP (1994) Clinical effects of serotonin reuptake inhibitors--a review. Fortschr Neurol Psychiatr 62(Suppl 1):9–15
Vaswani M, Kalra H (2004) Selective serotonin re-uptake inhibitors in anorexia nervosa. Expert Opin Investig Drugs 13:349–357
Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85–102
Barbeau A (1970) Dopamine and disease. Can Med Assoc J 103:824–832
Gainetdinov RR (2008) Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch Pharmacol 377:301–313
Gainetdinov RR, Caron MG (2003) Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43:261–284
Javitch JA, Snyder SH (1984) Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106:455–456
Foote SL, Aston-Jones G, Bloom FE (1980) Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci U S A 77:3033–3037
Schwartz JW, Piston D, DeFelice LJ (2006) Molecular microfluorometry: converting arbitrary fluorescence units into absolute molecular concentrations to study binding kinetics and stoichiometry in transporters. Handb Exp Pharmacol (175):23–57
Banks ML, Worst TJ, Rusyniak DE, Sprague JE (2014) Synthetic cathinones (“bath salts”). J Emerg Med 46:632–642
German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2–8
Miotto K, Striebel J, Cho AK, Wang C (2013) Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 132:1–12
Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, Carvalho F, Carvalho M (2014) Khat and synthetic cathinones: a review. Arch Toxicol 88:15–45
White KJ, Walline CC, Barker EL (2005) Serotonin transporters: implications for antidepressant drug development. AAPS J 7:E421–E433
Sghendo L, Mifsud J (2012) Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. J Pharm Pharmacol 64:317–325
Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215–235
Johansen PO, Krebs TS (2009) How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol 23:389–391
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439–452
Wall SC, Gu H, Rudnick G (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47:544–550
Wu X, Gu HH (1999) Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233:163–170
Henry LK, Blakely RD (2008) Distinctions between dopamine transporter antagonists could be just around the bend. Mol Pharmacol 73:616–618
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681–698
Burnette WB, Bailey MD, Kukoyi S, Blakely RD, Trowbridge CG, Justice JB Jr (1996) Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem 68:2932–2938
Holmes JC, Rutledge CO (1976) Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. Biochem Pharmacol 25:447–451
Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308–1317
Phillips AG, Brooke SM, Fibiger HC (1975) Effects of amphetamine isomers and neuroleptics on self-stimulation from the nucleus accumbens and dorsal noradrenergic bundle. Brain Res 85:13–22
Cody JT, Valtier S, Nelson SL (2003) Amphetamine enantiomer excretion profile following administration of Adderall. J Anal Toxicol 27:485–492
Heal DJ, Cheetham SC, Smith SL (2009) The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 57:608–618
Najib J (2009) The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 31:142–176
Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P 3rd, Everhart ET, Jones RT (2006) Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther 80:403–420
Potkin SG, Karoum F, Chuang LW, Cannon-Spoor HE, Phillips I, Wyatt RJ (1979) Phenylethylamine in paranoid chronic schizophrenia. Science 206:470–471
Romanelli F, Smith KM (2006) Clinical effects and management of methamphetamine abuse. Pharmacotherapy 26:1148–1156
Winslow BT, Voorhees KI, Pehl KA (2007) Methamphetamine abuse. Am Fam Physician 76:1169–1174
Mazei-Robinson MS, Blakely RD (2006) ADHD and the dopamine transporter: are there reasons to pay attention? Handb Exp Pharmacol (175):373–415
Arias HR (2009) Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 41:2098–2108
De Felice LJ (2016) Chloride requirement for monoamine transporters. Pflugers Arch 468:503–511
Singh SK (2008) LeuT: A prokaryotic stepping stone on the way to a eukaryotic neurotransmitter transporter structure. Channels (Austin) 2
Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD (1993) Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A 90:2542–2546
DeFelice LJ, Blakely RD (1996) Pore models for transporters? Biophys J 70:579–580
Galli A, Blakely RD, DeFelice LJ (1996) Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci U S A 93:8671–8676
Rudnick G (1998) Bioenergetics of neurotransmitter transport. J Bioenerg Biomembr 30:173–185
Rudnick G (1998) Ion-coupled neurotransmitter transport: thermodynamic vs. kinetic determinations of stoichiometry. Methods Enzymol 296:233–247
Naftalin RJ (1984) The thermostatics and thermodynamics of cotransport. Biochim Biophys Acta 778:155–175
Stein WD, Lieb WR (1986) Transport and diffusion across cell membranes. Academic, Orlando
Abramson J, Smirnova I, Kasho V, Verner G, Iwata S, Kaback HR (2003) The lactose permease of Escherichia coli: overall structure, the sugar-binding site and the alternating access model for transport. FEBS Lett 555:96–101
Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S (2003) Structure and mechanism of the lactose permease of Escherichia coli. Science 301:610–615
Penmatsa A, Wang KH, Gouaux E (2015) X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol 22:506–508
Wang KH, Penmatsa A, Gouaux E (2015) Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature 521:322–327
Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature 437:215–223
Yernool D, Boudker O, Jin Y, Gouaux E (2004) Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 431:811–818
Gu H, Wall SC, Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269:7124–7130
McElvain JS, Schenk JO (1992) A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem Pharmacol 43:2189–2199
Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17:960–974
Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A (2003) Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem 278:12070–12077
Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 102:3495–3500
Seidel S, Singer EA, Just H, Farhan H, Scholze P, Kudlacek O, Holy M, Koppatz K, Krivanek P, Freissmuth M, Sitte HH (2005) Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol Pharmacol 67:140–151
Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102–4108
Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60:527–535
Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2, E78
Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, Nikandrova Y, Bowton E, McMahon DG, Colbran RJ, Daws LC, Sitte HH, Javitch JA, Galli A, Gether U (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51:417–429
DeFelice LJ (2004) Going against the flow. Nature 432:279
DeFelice LJ, Goswami T (2007) Transporters as channels. Annu Rev Physiol 69:87–112
Quick MW (2003) Regulating the conducting states of a mammalian serotonin transporter. Neuron 40:537–549
Adams SV, DeFelice LJ (2002) Flux coupling in the human serotonin transporter. Biophys J 83:3268–3282
Adams SV, DeFelice LJ (2003) Ionic currents in the human serotonin transporter reveal inconsistencies in the alternating access hypothesis. Biophys J 85:1548–1559
DeFelice LJ, Galli A (1998) Electrophysiological analysis of transporter function. Adv Pharmacol 42:186–190
DeFelice LJ, Galli A (1998) Fluctuation analysis of norepinephrine and serotonin transporter currents. Methods Enzymol 296:578–593
Galli A, Blakely RD, DeFelice LJ (1998) Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake. Proc Natl Acad Sci U S A 95:13260–13265
Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD (1995) Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol 198:2197–2212
Li C, Zhong H, Wang Y, Wang H, Yang Z, Zheng Y, Liu K, Liu Y (2006) Voltage and ionic regulation of human serotonin transporter in Xenopus oocytes. Clin Exp Pharmacol Physiol 33:1088–1092
Mager S, Min C, Henry DJ, Chavkin C, Hoffman BJ, Davidson N, Lester HA (1994) Conducting states of a mammalian serotonin transporter. Neuron 12:845–859
Petersen CI, DeFelice LJ (1999) Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel. Nat Neurosci 2:605–610
Ramsey IS, DeFelice LJ (2002) Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor. J Biol Chem 277:14475–14482
Carvelli L, McDonald PW, Blakely RD, Defelice LJ (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proc Natl Acad Sci U S A 101:16046–16051
Ingram SL, Prasad BM, Amara SG (2002) Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat Neurosci 5:971–978
Quick MW (2002) Role of syntaxin 1A on serotonin transporter expression in developing thalamocortical neurons. Int J Dev Neurosci 20:219–224
Ryan RM, Mindell JA (2007) The uncoupled chloride conductance of a bacterial glutamate transporter homolog. Nat Struct Mol Biol 14:365–371
Sonders MS, Amara SG (1996) Channels in transporters. Curr Opin Neurobiol 6:294–302
Bruns D (1998) Serotonin transport in cultured leech neurons. Methods Enzymol 296:593–607
Bruns D, Engert F, Lux HD (1993) A fast activating presynaptic reuptake current during serotonergic transmission in identified neurons of Hirudo. Neuron 10:559–572
Rodriguez-Menchaca AA, Solis E Jr, Cameron K, De Felice LJ (2012) S(+)amphetamine induces a persistent leak in the human dopamine transporter: molecular stent hypothesis. Br J Pharmacol 165:2749–2757
Wang HW, Li CZ, Yang ZF, Zheng YQ, Zhang Y, Liu YM (2006) Electrophysiological effect of fluoxetine on Xenopus oocytes heterologously expressing human serotonin transporter. Acta Pharmacol Sin 27:289–293
Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004) R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142:172–180
Lin F, Lester HA, Mager S (1996) Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation. Biophys J 71:3126–3135
Barker EL, Moore KR, Rakhshan F, Blakely RD (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 19:4705–4717
Sandtner W, Schmid D, Schicker K, Gerstbrein K, Koenig X, Mayer FP, Boehm S, Freissmuth M, Sitte HH (2014) A quantitative model of amphetamine action on the 5-HT transporter. Br J Pharmacol 171:1007–1018
De Felice LJ, Cameron KN (2015) Comments on ‘A quantitative model of amphetamine action on the serotonin transporter’, by Sandtner et al., Br J Pharmacol 171: 1007–1018. Br J Pharmacol 172:4772–4774
Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562
Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213
Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180–187
Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803–1815
Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470
Simmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152–160
Cameron KN, Kolanos R, Solis E Jr, Glennon RA, De Felice LJ (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750–1757
Kolanos R, Solis E Jr, Sakloth F, De Felice LJ, Glennon RA (2013) “Deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem Neurosci 4:1524–1529
Bulling S, Schicker K, Zhang YW, Steinkellner T, Stockner T, Gruber CW, Boehm S, Freissmuth M, Rudnick G, Sitte HH, Sandtner W (2012) The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem 287:18524–18534
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4